Seminars in Nephrology
Volume 24, Issue 2 , Pages 120-130 , March 2004

Angiotensin II receptor type 1 expression in erythroid progenitors: implications for the pathogenesis of postrenal transplant erythrocytosis

  • Michal Mrug

      Affiliations

    • Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA
    • ,
  • Bruce A Julian

      Affiliations

    • Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA
    • ,
  • Josef T Prchal

      Affiliations

    • Division of Hematology, Baylor College of Medicine, Houston, TX, USA
    • Corresponding Author InformationAddress reprint requests to Josef T. Prchal, Hematology, 802E, 1 Baylor Plaza, Baylor College of Medicine, Houston, TX 77030 USA

References 

  1. Gregory CJ, Eaves AC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood. 1978;51:527–537
  2. Wickrema A, Krantz SB, Winkelmann JC, et al.  Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood. 1992;80:1940–1949
  3. Sawada K, Krantz SB, Dai CH, et al.  Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol. 1990;142:219–230
  4. Ang SO, Chen H, Hirota K, et al.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614–621
  5. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167–171
  6. Epstein AC, Gleadle JM, McNeill LA, et al.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54
  7. Ivan M, Kondo K, Yang H, et al.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation (Implications for O2 sensing). Science. 2001;292:464–468
  8. Jaakkola P, Mole DR, Tian YM, et al.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472
  9. Cashman JD, Eaves AC, Raines EW, et al.  Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood. 1990;75:96–101
  10. Shao L, Frigon NL, Young AL, et al.  Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood. 1992;79:773–781
  11. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science. 1987;236:1229–1237
  12. Bernstein A, Forrester L, Reith AD, et al.  The murine W/c-kit and Steel loci and the control of hematopoiesis. Semin Hematol. 1991;28:138–142
  13. Mrug M, Stopka T, Julian BA, et al.  Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100:2310–2314
  14. Malgor LA, Valsecia M, Verges E, et al.  Blockade of the in vitro effects of testosterone and erythropoietin on Cfu-E and Bfu-E proliferation by pretreatment of the donor rats with cyproterone and flutamide. Acta Physiol Pharmacol Ther Latinoam. 1998;48:99–105
  15. Kaushansky K, Broudy VC, Grossmann A, et al.  Thrombopoietin expands erythroid progenitors, increases red cell production and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest. 1995;96:1683–1687
  16. Le Meur Y, Lorgeot V, Comte L, et al.  Plasma levels and metabolism of AcSDKP in patients with chronic renal failure (Relationship with erythropoietin requirements). Am J Kidney Dis. 2001;38:510–517
  17. Kanasaki K, Koya D, Sugimoto T, et al.  N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol. 2003;14:863–872
  18. Onoyama K, Sanai T, Motomura K, et al.  Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol. 1989;13(suppl 3):S27–S30
  19. Bailey RR, Sizeland PC. ACE inhibitor anaemia. N Z Med J. 1989;102:232
  20. Verhaaren HA, Vande Walle J, Devloo-Blancquaert A. Captopril in severe childhood hypertension-Reversible anaemia with high dosage. Eur J Pediatr. 1986;144:554–556
  21. Sizeland PC, Bailey RR, Lynn KL, et al.  Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients. J Cardiovasc Pharmacol. 1990;16(Suppl 7):S117–S119
  22. Gossmann J, Kachel HG, Schoeppe W, et al.  Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation. 1993;56:585–589
  23. Vlahakos DV, Canzanello VJ, Madaio MP, et al.  Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis. 1991;17:199–205
  24. Hu RH, Lee PH, Lee CJ. Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril. Transplant Proc. 1996;28:1545–1547
  25. Montanaro D, Gropuzzo M, Tulissi P, et al.  Angiotensin-converting enzyme inhibitors reduce hemoglobin concentrations, hematocrit, and serum erythropoietin levels in renal transplant recipients without posttransplant erythrocytosis. Transplant Proc. 2001;33:2038–2040
  26. Glicklich D, Burris L, Urban A, et al.  Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol. 2001;12:1958–1964
  27. Morrone LF, Di Paolo S, Logoluso F, et al.  Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients (Role of growth factors and cytokines). Transplantation. 1997;64:913–918
  28. Conlon PJ, Farrell J, Donohoe J, et al.  The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation. 1993;56:217–219
  29. Gossmann J, Thurmann P, Bachmann T, et al.  Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int. 1996;50:973–978
  30. Kessler M, Hestin D, Mayeux D, et al.  Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol. 1996;45:83–89
  31. Danovitch GM, Jamgotchian NJ, Eggena PH, et al.  Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation. 1995;60:132–137
  32. Perazella M, McPhedran P, Kliger A, et al.  Enalapril treatment of posttransplant erythrocytosis (Efficacy independent of circulating erythropoietin levels). Am J Kidney Dis. 1995;26:495–500
  33. Rodgers KE, Xiong S, Steer R, et al.  Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287–294
  34. Glezerman I, Patel H, Glicklich D, et al.  Angiotensin-converting enzyme inhibition induces death receptor apoptotic pathways in erythroid precursors following renal transplantation. Am J Nephrol. 2003;23:195–201
  35. Cole J, Ertoy D, Lin H, et al.  Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest. 2000;106:1391–1398
  36. Anagnostou A, Baranowski R, Pillay VK, et al.  Effect of renin on extrarenal erythropoietin production. J Lab Clin Med. 1976;88:707–715
  37. Nakao K, Shirakura T, Azuma M, et al.  Studies on erythropoietic action of angiotensin II. Blood. 1967;29:754–760
  38. Fisher JW, Samuels AI, Langston JW. Effects of angiotensin and renal artery constriction on erythropoietin production. J Pharmacol Exp Ther. 1967;157:618–625
  39. Fried W, Barone-Varelas J, Barone T, et al.  Extraction of erythropoietin from kidneys. Exp Hematol. 1980;8(suppl 8):41–51
  40. Gould AB, Goodman S, DeWolf R, et al.  Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med. 1980;96:523–534
  41. Gossmann J, Burkhardt R, Harder S, et al.  Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int. 2001;60:83–86
  42. Freudenthaler SM, Schreeb K, Korner T, et al.  Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest. 1999;29:816–823
  43. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis. 2001;38:415–425
  44. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90:4304–4308
  45. Jackson TR, Blair LA, Marshall J, et al.  The mas oncogene encodes an angiotensin receptor. Nature. 1988;335:437–440
  46. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest. 1994;93:788–798
  47. Rodgers K, Xiong S, Felix J, et al.  Development of angiotensin (1–7) as an agent to accelerate dermal repair. Wound Repair Regen. 2001;9:238–247
  48. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res. 1992;70:820–828
  49. Nakahara K, Nishimura H, Kuro-O M, et al.  Identification of three types of PDGF-A chain gene transcripts in rabbit vascular smooth muscle and their regulated expression during development and by angiotensin II. Biochem Biophys Res Commun. 1992;184:811–818
  50. Gupta M, Miller BA, Ahsan N, et al.  Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplantation. 2000;70:1188–1194
  51. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin (1–7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol. 2003;51:97–106
  52. Azizi M, Rousseau A, Ezan E, et al.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839–844
  53. De Paolis P, Porcellini A, Savoia C, et al.  Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens. 2002;20:693–699
  54. Carroll MP, Spivak JL, McMahon M, et al.  Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem. 1991;266:14964–14969
  55. Okuda M, Kawahara Y, Yokoyama M. Angiotensin II type I receptor-mediated activation of Ras in cultured rat vascular smooth muscle cells. Am J Physiol. 1996;271:H595–H601
  56. Fischer TA, Singh K, O’Hara DS, et al.  Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol. 1998;275:H906–H916
  57. Gobert S, Duprez V, Lacombe C, et al.  The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem. 1995;234:75–83
  58. Marrero MB, Schieffer B, Paxton WG, et al.  Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 1995;375:247–250
  59. Wang Y, Morella KK, Ripperger J, et al.  Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or STAT3. Blood. 1995;86:1671–1679
  60. Wang Y, Fuller GM. Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes. Mol Biol Cell. 1994;5:819–828
  61. Quelle FW, Sato N, Witthuhn BA, et al.  JAK2 associates with the β c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994;14:4335–4341
  62. Linnekin D, Weiler SR, Mou S, et al.  JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor. Acta Haematol. 1996;95:224–228
  63. Jiang N, He TC, Miyajima A, et al.  The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 β-receptor chimera. J Biol Chem. 1996;271:16472–16476
  64. Miller BA, Bell L, Hansen CA, et al.  G-protein α subunit Gi(α)2 mediates erythropoietin signal transduction in human erythroid precursors. J Clin Invest. 1996;98:1728–1736
  65. Loutzenhiser K, Loutzenhiser R. Angiotensin II-induced Ca(2+) influx in renal afferent and efferent arterioles (differing roles of voltage-gated and store-operated Ca(2+) entry). Circ Res. 2000;87:551–557
  66. Carozzi S, Grazia Nasini M, Salit M, et al.  Ca(++)-induced modulation of erythropoiesis in polycythemic transplanted patients. Transplant Proc. 1991;23:1309–1311
  67. Stopka T, Zivny JH, Stopkova P, et al.  Human hematopoietic progenitors express erythropoietin. Blood. 1998;91:3766–3772
  68. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol. 2001;38:10–20
  69. Thevenod F, Radtke HW, Grutzmacher P, et al.  Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia. Kidney Int. 1983;24:227–232
  70. Dagher FJ, Ramos E, Erslev AJ, et al.  Are the native kidneys responsible for erythrocytosis in renal allorecipients?. Transplantation. 1979;28:496–498
  71. Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis (An enigma revisited). Am J Kidney Dis. 1994;24:1–11
  72. Lezaic V, Biljanovic-Paunovic L, Pavlovic-Kentera V, et al.  Erythropoiesis after kidney transplantation (The role of erythropoietin, burst promoting activity and early erythroid progenitor cells). Eur J Med Res. 2001;6:27–32
  73. Lezaic V, Djukanovic LJ, Pavlovic-Kentera V, et al.  Factors inducing posttransplant erythrocytosis. Eur J Med Res. 1997;2:407–412
  74. Qunibi WY, Barri Y, Devol E, et al.  Factors predictive of post-transplant erythrocytosis. Kidney Int. 1991;40:1153–1159
  75. Sumrani NB, Daskalakis P, Miles AM, et al.  Erythrocytosis after renal transplantation. A prospective analysis. ASAIO J. 1993;39:51–55
  76. Friman S, Nyberg G, Blohme I. Erythrocytosis after renal transplantation; treatment by removal of the native kidneys. Nephrol Dial Transplant. 1990;5:969–973
  77. Aeberhard JM, Schneider PA, Vallotton MB, et al.  Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation. 1990;50:613–616
  78. Julian BA, Gaston RS, Barker CV, et al.  Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int. 1994;46:1397–1403
  79. Gaston RS, Julian BA, Barker CV, et al.  Enalapril (Safe and effective therapy for posttransplant erythrocytosis). Transplant Proc. 1993;25:1029–1031
  80. Sauron C, Berthoux P, Berthoux F, et al.  New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc. 1993;25:1032–1033
  81. Glicklich D, Kapoian T, Mian H, et al.  Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation. 1999;68:62–66
  82. Teruel JL, Marcen R, Navarro JF, et al.  Evolution of serum erythropoietin after androgen administration to hemodialysis patients (A prospective study). Nephron. 1995;70:282–286
  83. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension. 1992;19:456–463
  84. Yanase T, Maki T, Nawata H, et al.  Effect of angiotensin II on secretion of adrenal androgens. Endocrinol Jpn. 1984;31:741–747
  85. Wang AY, Yu AW, Lam CW, et al.  Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis. 2002;39:600–608
  86. Montanaro D, Groupuzzo M, Boscutti G, et al.  Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors (Efficacy, safety and action mechanisms). Clin Nephrol. 2000;53:47–51
  87. Calvino J, Lens XM, Romero R, et al.  Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant. 2000;15:82–86
  88. Shih LY, Huang JY, Lee CT. Insulin-like growth factor 1 plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol. 1999;10:315–322
  89. Muller C, Reddert A, Wassmann S, et al.  Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst. 2000;1:273–277
  90. Lamperi S, Carozzi S. Erythroid progenitor growth in erythrocytosic transplanted patients. Artif Organs. 1985;9:200–204
  91. Rostaing L, Demur C, Huyn A, et al.  Erythrocytosis after renal transplant (Study of erythroid progenitors and response to enalapril). Transplant Proc. 1994;26:280–281
  92. Smalcelj R, Kusec V, Thune S, et al.  Circulating hematopoietic progenitors are not altered in patients with post-transplant erythrocytosis. Haematologica. 1998;83:948–949
  93. Hestin D, Gregoire MJ, Mayeux D, et al.  In-vitro growth patterns of bone marrow erythroid progenitors from patients with post-renal transplant erythrocytosis. Nephrol Dial Transplant. 1998;13:1776–1781
  94. Ducloux D, Saint-Hillier Y, Chalopin JM. Effect of losartan on haemoglobin concentration in renal transplant recipients—a retrospective analysis. Nephrol Dial Transplant. 1997;12:2683–2686
  95. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene (evidence that the oxygen sensor is a heme protein). Science. 1988;242:1412–1415
  96. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378–381

PII: S0270-9295(03)00196-7

doi: 10.1016/j.semnephrol.2003.11.006

Seminars in Nephrology
Volume 24, Issue 2 , Pages 120-130 , March 2004

Article Tools

* Image Usage & Resolution